Mcgowan Group Asset Management Has Upped Its Stake in Information Services Grp (III) as Share Price Rose; Esperion Therapeutics (ESPR) Holder Meditor Group LTD Has Upped Its Stake by $2.25 Million

Information Services Group, Inc. (NASDAQ:III) Logo

Meditor Group Ltd increased its stake in Esperion Therapeutics Inc (ESPR) by 1.9% based on its latest 2018Q4 regulatory filing with the SEC. Meditor Group Ltd bought 50,000 shares as the company’s stock declined 11.78% while stock markets rallied. The institutional investor held 2.68 million shares of the health care company at the end of 2018Q4, valued at $123.27M, up from 2.63M at the end of the previous reported quarter. Meditor Group Ltd who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.34 billion market cap company. The stock increased 1.71% or $0.84 during the last trading session, reaching $49.87. About 636,695 shares traded or 7.24% up from the average. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 39.96% since March 17, 2018 and is downtrending. It has underperformed by 44.33% the S&P500. Some Historical ESPR News: 14/05/2018 – The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR); 27/03/2018 – ESPERION PHASE 2 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT; 02/05/2018 – Esperion Therapeutics Cash and Cash Equivalents and Investment Securities Available-For-Sale Totaled $239.6M at March 31; 03/04/2018 – Esperion Therapeutics at Non-Deal Roadshow Hosted By Chardan; 24/05/2018 – The Klein Law Firm Announces a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR); 02/05/2018 – ESPERION MET PRIMARY ENDPOINT OF SAFETY & TOLERABILITY; 24/05/2018 – The Klein Law Firm Announces a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintif; 07/03/2018 – Esperion: LDL-C Lowering for Bempedoic Acid Group Was 23 % From Baseline; 14/05/2018 – DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. – ESPR; 10/05/2018 – Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference

Mcgowan Group Asset Management Inc increased its stake in Information Services Grp (III) by 161.5% based on its latest 2018Q4 regulatory filing with the SEC. Mcgowan Group Asset Management Inc bought 101,489 shares as the company’s stock rose 3.35% with the market. The institutional investor held 164,332 shares of the consumer services company at the end of 2018Q4, valued at $697,000, up from 62,843 at the end of the previous reported quarter. Mcgowan Group Asset Management Inc who had been investing in Information Services Grp for a number of months, seems to be bullish on the $162.67M market cap company. The stock decreased 14.49% or $0.61 during the last trading session, reaching $3.6. About 439,305 shares traded or 533.16% up from the average. Information Services Group, Inc. (NASDAQ:III) has risen 2.37% since March 17, 2018 and is uptrending. It has underperformed by 2.00% the S&P500. Some Historical III News: 14/03/2018 – Info Services Group 4Q Adj EPS 0c; 09/05/2018 – INFORMATION SERVICES GROUP INC – REAFFIRMS FULL-YEAR GUIDANCE FOR REVENUES AND ADJUSTED EBITDA; 09/03/2018 – ISG Invites Nominations for Inaugural ISG Paragon Awards™ Program in the Americas; 13/03/2018 – Digital Retailing the Focus of ISG Webinar on March 14; 09/05/2018 – Info Services Group 1Q Rev $68.9M; 09/05/2018 – Info Services Group 1Q Adj EPS 5c; 14/03/2018 – Info Services Group 4Q Rev $66.6M; 16/04/2018 – ISG Announces Finalists for Inaugural ISG Paragon Awards™ Program in the Americas; 26/04/2018 – ISG Event Explores Digital Future of Work; 29/03/2018 – Demands of Digital Business Driving Growth in Data Center Services, Says ISG Research Report

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Nasdaq.com which released: “Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions – Nasdaq” on March 04, 2019, also Seekingalpha.com with their article: “Esperion completes marketing applications for bempedoic acid – Seeking Alpha” published on February 28, 2019, Globenewswire.com published: “Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation – GlobeNewswire” on January 29, 2019. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Benzinga.com and their article: “5 Biggest Price Target Changes For Wednesday – Benzinga” published on March 13, 2019 as well as Nasdaq.com‘s news article titled: “Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine – Nasdaq” with publication date: March 13, 2019.

Meditor Group Ltd, which manages about $485.47 million US Long portfolio, decreased its stake in Alkermes Plc (NASDAQ:ALKS) by 138,239 shares to 892,400 shares, valued at $26.33 million in 2018Q4, according to the filing.

Investors sentiment decreased to 1 in Q4 2018. Its down 0.11, from 1.11 in 2018Q3. It turned negative, as 22 investors sold ESPR shares while 40 reduced holdings. 23 funds opened positions while 39 raised stakes. 24.06 million shares or 2.18% less from 24.60 million shares in 2018Q3 were reported. Cim Investment Mangement Inc invested 0.14% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). C Worldwide Gp A S reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Jpmorgan Chase And reported 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Moreover, Hall Laurie J Trustee has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Of Wisconsin Board reported 23,400 shares stake. Citigroup holds 0.01% or 241,087 shares in its portfolio. Sg Americas reported 4,405 shares. Paloma Prtn Mngmt has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Wasatch Advisors invested in 0.34% or 562,624 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,351 shares. Riverhead Mngmt Limited Company stated it has 366 shares or 0% of all its holdings. Art Advisors Limited Co invested in 50,443 shares or 0.15% of the stock. 27,900 are held by California Public Employees Retirement Sys. Granahan Inv Mngmt Ma reported 108,200 shares stake. 22 are held by Northwestern Mutual Wealth Mngmt Communication.

Investors sentiment decreased to 1.31 in 2018 Q4. Its down 1.06, from 2.37 in 2018Q3. It dived, as 11 investors sold III shares while 18 reduced holdings. 15 funds opened positions while 23 raised stakes. 21.18 million shares or 6.83% less from 22.73 million shares in 2018Q3 were reported. 25,300 are held by Acg Wealth. Perritt Management has 481,215 shares. Northern Tru owns 382,933 shares. Punch And Assoc Investment Mngmt stated it has 0.38% in Information Services Group, Inc. (NASDAQ:III). Dimensional Fund Advsrs Limited Partnership holds 487,248 shares or 0% of its portfolio. 82,582 are owned by Wells Fargo And Co Mn. Price T Rowe Associate Inc Md has 0% invested in Information Services Group, Inc. (NASDAQ:III). Wetherby Asset Mgmt Inc has invested 0.12% of its portfolio in Information Services Group, Inc. (NASDAQ:III). California Employees Retirement Sys owns 130,200 shares. State Street reported 0% stake. Prudential Fin Incorporated invested in 0% or 11,535 shares. Moreover, Susquehanna Interest Group Inc Limited Liability Partnership has 0% invested in Information Services Group, Inc. (NASDAQ:III). Mcgowan Gp Asset Mngmt reported 164,332 shares or 0.13% of all its holdings. Zebra Mngmt Ltd Llc stated it has 19,228 shares or 0.05% of all its holdings. Ameritas Invest Prtn Incorporated holds 0% or 2,421 shares.

More notable recent Information Services Group, Inc. (NASDAQ:III) news were published by: Nasdaq.com which released: “Indonesia’s Lippo Karawaci to raise $1 bln in funding, names CEO – Nasdaq” on March 12, 2019, also Seekingalpha.com with their article: “Information Services Group, Inc. (III) CEO Michael Connors on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on March 15, 2019, Nasdaq.com published: “Phase III Drilling Targets to Expand Zones on Chimo Mine Project – Nasdaq” on March 14, 2019. More interesting news about Information Services Group, Inc. (NASDAQ:III) were released by: Nasdaq.com and their article: “Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin – Nasdaq” published on March 01, 2019 as well as Nasdaq.com‘s news article titled: “AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag – Nasdaq” with publication date: March 15, 2019.

Information Services Group, Inc. (NASDAQ:III) Institutional Positions Chart